TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22269534
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MDMA
Study: 10622275
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 mg/kg)
Study: 7860949
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sodium PHT plus 1 mg folic acid per day
Study: 7860949
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sodium PHT per day
Study: 1949301
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue plasminogen activator (tPA) (100 mg over 3 hours)
Study: 1949301
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (12,500 U twice daily)
Study: 17475736
Drug: Interpersonal psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal psychotherapy plus pharmacotherapy
Study: 17475736
Drug: Clinical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical management (medication plus intensive clinical management)
Study: 7645553
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of antibody concentrations post-vaccination
Study: 334604
Drug: Ketoprofen (Orudis)
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoprofen (Orudis) 100 mg suppository nightly for ten days
Study: 334604
Drug: Indomethacin suppository
Normalized name: indomethacin Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin suppository nightly for ten days
Study: 21362108
Drug: nabiximols (Sativex)
Normalized name: Castanea sative leaf extract
DrugBank: Nabiximols (DB14011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nabiximols (Sativex) as add-on therapy
Study: 18164919
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 100 mg, 200 mg, and 300 mg
Study: 18164919
Drug: Tramadol ER
Normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol ER 200 mg and 300 mg
Study: 15181043
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution (control)
Study: 11773991
Drug: Spirapril 3
Normalized name: spirapril 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 3 mg once a day
Study: 11773991
Drug: Spirapril 6
Normalized name: spirapril 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril 6 mg once a day
Study: 101317
Drug: Aqueous pollen
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous pollen extract (SDV), 18 doses
Study: 101317
Drug: Glutaraldehyde-treated pollen-tyrosine
Normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutaraldehyde-treated pollen-tyrosine adsorbate (Pollinex), 3 doses
Study: 31682941
Drug: Digital DPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital DPP (small group support, personalized health coaching, digital tracking tools, weekly behavior change curriculum)
Study: 24778436
Drug: Baby Triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby Triple P (8 sessions) + Treatment as Usual (TAU)
Study: 17908750
Drug: Increase in
Normalized name: Incruse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increase in breast milk ingestion (10 mL/kg per day)
Study: 16225606
Drug: Excimer laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer laser treatment (twice weekly)
Study: 16225606
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) treatment (every 4 weeks, pretreated with salicylic acid)
Study: 9059669
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid treatment for 4 weeks
Study: 3567121
Drug: Oxytocin titration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin titration to achieve a preset frequency of 6-7 uterine contractions every 15 min
Study: 3567121
Drug: Oxytocin titration
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin titration to achieve uterine activity equivalent to the 75th centile for spontaneous labour
Study: 21406450
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood injection (ABI)
Study: 19136752
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with bupivacaine and sufentanil combination
Study: 2553235
Drug: Weekly doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly doxorubicin (ADR)
Study: 960908
Drug: +)-cyanidanol-3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: +)-cyanidanol-3 (2 g daily, administered orally)
Study: 960908
Drug: +)-cyanidanol-3 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: +)-cyanidanol-3 (1 g daily)
Study: 23945134
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) 4 or 8 mg/kg every four weeks
Study: 19965519
Drug: Interferon-beta 1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-beta 1a (intramuscular)
Study: 19965519
Drug: Previous interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous interferon-beta preparation (subcutaneous)
Study: 11187583
Drug: In-patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-patient treatment
Study: 17978324
Drug: Specialist out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specialist out-patient treatment
Study: 20334748
Drug: General CAMHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: General CAMHS treatment
Study: 9494148
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg orally per day
Study: 9494148
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg orally per day
Study: 9494148
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg orally twice a day
Study: 9494148
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg per day (maintenance)
Study: 9494148
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice a day (maintenance)
Study: 8307222
Drug: Acetylsalicylic acid/dipyridamole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetylsalicylic acid/dipyridamole (50 mg/400 mg daily)
Study: 30884964
Drug: 3‐OHB infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3‐OHB infusion
Study: 27798513
Drug: Everolimus (EVL)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVL) with target trough level (Ctrough, 3‐8 ng/mL), prednisone, and tacrolimus (TCL) (target Ctrough, 2‐5 ng/mL)
Study: 22582933
Drug: Psychotropic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotropic medications (specific drugs not mentioned)
Study: 19545249
Drug: MAP0004 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 0.5 mg
Study: 19545249
Drug: MAP0004 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP0004 1.0 mg
Study: 17314579
Drug: Ketamine (0.3%,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.3%, 3 mL)
Study: 11474143
Drug: 10% oral
Normalized name: Xylocaine 10% Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% oral glucose plus sucking
Study: 9684795
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) injection, doses ranging from 5 to 320 microg/kg
Study: 9684795
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) injection, doses < or = 20 microg/kg
Study: 9684795
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) injection, doses > 20 microg/kg
Study: 9684795
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa) injection
Study: 7766962
Drug: Food A
Normalized name: Food allergenic extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food A (3.12 g protein equivalent per 100 kcal)
Study: 7766962
Drug: Food B
Normalized name: Real Food Blends Eggs Apples & Oats
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food B (2.74 g protein equivalent per 100 kcal)
Study: 3144009
Drug: Protein supply
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein supply (1 g protein/kg.d) and 1-carnitine (2 g/day)
Study: 28343938
Drug: Testosterone (T)
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone (T) administered 2-3 hours prior to testing
Study: 28343938
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 2-3 hours prior to testing
Study: 23952097
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol (1 g IV every 8 hours for up to 24 hours)
Study: 20147742
Drug: Prediction model
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prediction model including large tumor cell fragments (L-TCF), age, hemoglobin and lactate dehydrogenase
Study: 20147742
Drug: Models with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Models with S-TMP or CTC instead of L-TCF
Study: 8157902
Drug: Lidocaine (bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (bolus i.v. of 1 mg/kg, followed by an infusion of 4 mg/min)
Study: 8157902
Drug: Placebo (infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (infusion of saline at a rate of 1 mL/min)
Study: 3530156
Drug: Chloroquine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (10 mg base kg-1)
Study: 3530156
Drug: Chlorproguanil (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorproguanil (1.5 mg kg-1)
Study: 3530156
Drug: Placebo (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (vitamin tablets)
Study: 28884824
Drug: Anacetrapib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib (5 to 500 mg)
Study: 2209920
Drug: Topical flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical flurbiprofen
Study: 2651233
Drug: Nifedipine titrated
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine titrated to 60 mg/day
Study: 793562
Drug: Dextroamphetamine sulfate,
Normalized name: Dextroamphetamine Sulfate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate, 20 mg orally daily at 8 PM
Study: 793562
Drug: Dextroamphetamine sulfate,
Normalized name: Dextroamphetamine Sulfate, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate, up to 40 mg orally
Study: 23528880
Drug: Comprehensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive group program (psychoeducation, cognitive rehabilitation, cognitive behavioral therapy)
Study: 8333598
Drug: Acute dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute dose of alcohol
Study: 3447334
Drug: No antimetabolite
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimetabolite treatment
Study: 29414735
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with topical application of 50 μl toluidine blue (1 mg/ml) followed by laser irradiation using GaAlAs laser (630 nm, 10 mW/cm2)
Study: 29414735
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) using diode laser (630 nm, 10 mW)
Study: 29414735
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid application (dexamethasone 0.5 mg in 5 ml water mouthwash for 5 min)
Study: 22906262
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg tamsulosin plus 0.5 mg dutasteride
Study: 20876171
Drug: Nebulized epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized epinephrine plus oral dexamethasone
Study: 2679853
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone alone
Study: 12570938
Drug: Fasudil (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasudil (4.5 mg intracoronarily)
Study: 12045833
Drug: Pyridostigmine (PYR)
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridostigmine (PYR) 45 mg
Study: 1991701
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at a dose of 250 mg/m2/day for 12 weeks
Study: 6127861
Drug: Nadolol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 2% solution
Study: 6127861
Drug: Timolol 0.25%
Normalized name: Timolol 0.25% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.25% solution
Study: 19528154
Drug: 3 day
Normalized name: Kathro 3 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 day amoxicillin treatment
Study: 19528154
Drug: 7 day
Normalized name: ZonaCort 7 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 day amoxicillin treatment
Study: 10193369
Drug: Pranlukast (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast (225 mg orally twice per day for four weeks)
Study: 30571173
Drug: Low-dose methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methotrexate (15 mg/wk)
Study: 27475837
Drug: Icon condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icon condition (acetaminophen medications marked with an icon)
Study: 24273022
Drug: Epratuzumab 360
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab 360 mg/m2
Study: 24273022
Drug: Epratuzumab 720
Normalized name: Epratuzumab
DrugBank: Epratuzumab (DB04958)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epratuzumab 720 mg/m2
Study: 22027612
Drug: Adaptol 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptol 500 mg, 2 times daily in addition to regular vasoactive treatment
Study: 19006592
Drug: Colchicine mouthwash
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine mouthwash (2 mg daily for 5 days)
Study: 14570343
Drug: Cefazolin plus
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin plus metronidazole (1 g cefazolin + 500 mg metronidazole)
Study: 10817729
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of abacavir
Study: 10817729
Drug: 0.7 g
Normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g of ethanol per kg of body weight
Study: 10817729
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of abacavir and 0.7 g of ethanol per kg
Study: 8872401
Drug: Half-age energy
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-age energy dosing (7 J, 30% higher than titration estimates)
Study: 8872401
Drug: Threshold titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Threshold titration
Study: 8872401
Drug: Half-age energy
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-age energy dosing
Study: 1325574
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy (4 weeks or 8 weeks arm of treatment with ACT D and VCR)
Study: 1325574
Drug: Pre-operative chemotherapy
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative chemotherapy
Study: 31425966
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT)
Study: 30184600
Drug: Cytoreductive nephrectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoreductive nephrectomy (CN) followed by interferon therapy
Study: 24592952
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc gluconate (26 mg zinc twice daily for 14 days)
Study: 23303986
Drug: Diazoxide 100
Normalized name: diazoxide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide 100 mg orally three times daily for 10 days
Study: 8826981
Drug: Diazoxide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazoxide treatment
Study: 18038603
Drug: Standard antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antituberculosis therapy (Group 1)
Study: 18038603
Drug: Standard antituberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antituberculosis therapy + paravasal lymphotrophic immunological correction (Group 2)
Study: 18038603
Drug: Individual regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual regimens of antituberculous drugs (Group 3)
Study: 15510746
Drug: FK‐506 eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: FK‐506 eyedrops (0.5 mg/ml) and TobraDex eyedrops
Study: 7625343
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group fed formulas with protein-energy ratios of 3.73 g/MJ (1.56 g/100 kcal) from 8 to 27 days, decreasing to 2.99 g/MJ (1.25 g/100 kcal) from 84 to 111 days.
Study: 357213
Drug: Ro 10‐9359
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 10‐9359 at 25 mg t.i.d.
Study: 357213
Drug: Ro 10‐9359
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 10‐9359 at 50 mg b.i.d.
Study: 18381513
Drug: Hypothermia (33
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia (33 degrees C to 34 degrees C) for 72 hours with continuous morphine infusion
Study: 18381513
Drug: Normothermia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normothermia with continuous morphine infusion
Study: 18381513
Drug: Hypothermia with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypothermia with morphine infusion rate >10 microg/kg per h
Study: 11910617
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein dietary supplements containing 118 mg of isoflavones (daidzein, genistein, glycitein and their respective glycosides)
Study: 1282364
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha therapy (3 million units daily for the first month, then thrice weekly for 5 months)
Study: 11145854
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha therapy
Study: 1282364
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha therapy and Control group
Study: 6374403
Drug: Triple intrathecal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple intrathecal (IT) chemotherapy (methotrexate, hydrocortisone, cytosine arabinoside) starting on day 1 of treatment (Arm 3)
Study: 6374403
Drug: Triple IT
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple IT chemoprophylaxis during induction therapy (Arm 3)
Study: 27358142
Drug: Lactulose oral
Normalized name: lactulose Oral Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose oral solution
Study: 29669139
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg + furosemide 20 mg
Study: 29669139
Drug: Nutritional counseling
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional counseling to sodium-restricted diet plus placebo pill
Study: 26482684
Drug: Modified Ranawat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Ranawat suspension
Study: 17432691
Drug: Terazosin tablet
Normalized name: Terazosin Tablets
DrugBank: Terazosin (DB01162)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terazosin tablet for 60 days
Study: 10363731
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion SR 150 to 400 mg/d
Study: 10363731
Drug: sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sertraline 50 to 200 mg/d
Study: 7734255
Drug: 1% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mepivacaine with adrenaline 40 ml, arm adducted
Study: 7734255
Drug: 1% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% mepivacaine with adrenaline 40 ml, arm abducted
Study: 7734255
Drug: 2% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm adducted
Study: 7734255
Drug: 2% mepivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% mepivacaine 20 ml mixed with contrast agent 20 ml, arm abducted
Study: 6112602
Drug: D-penicillamine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (600 mg daily)
Study: 28594575
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (previously intensified treatment)
Study: 19374211
Drug: Ephedrine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (Group E, n = 30, dose = 10 mg)
Study: 19374211
Drug: Phenylephrine (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (Group P, n = 30, dose = 80 microg)
Study: 21959663
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (group II)
Study: 11326796
Drug: Calcium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium intake of 900 mg/day